Littlewood T J
Department of Haematology, Oxford Radcliffe NHS Trust, Oxford OX3 9DU, UK.
Hematol Oncol. 2001 Mar;19(1):19-30. doi: 10.1002/hon.663.
Anemia is common in patients with hematological malignancy. Most patients will have their anemia attributed to the anemia of chronic disease. The anemia of chronic disease is caused by cytokine mediated suppression of erythropoiesis and low serum erythropoietin levels are found in the majority of patients with cancer. Many of these anemic patients will be symptomatic with fatigue. Data from many studies indicates that treatment of anemic patients with erythropoietin will increase their hemoglobin concentration, decrease transfusion need and also improve their quality of life. A recent study also suggests that improving the hemoglobin level may improve the patients' prognosis but this finding needs to be confirmed.
贫血在血液系统恶性肿瘤患者中很常见。大多数患者的贫血归因于慢性病贫血。慢性病贫血是由细胞因子介导的红细胞生成抑制引起的，大多数癌症患者血清促红细胞生成素水平较低。这些贫血患者中的许多人会出现疲劳症状。许多研究数据表明，用促红细胞生成素治疗贫血患者会提高其血红蛋白浓度，减少输血需求，并改善他们的生活质量。最近的一项研究还表明，提高血红蛋白水平可能会改善患者的预后，但这一发现需要得到证实。
